Leadership

Mark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.

Aditya is the inventor of HDPCR, ChromaCode’s core technology. Previously, he was a researcher at Google[x], where he worked on novel medical imaging methods. He has expertise in thermal engineering, digital signal processing, nano-scale electronics, low-power circuit design for implantable sensors, DNA sequencing structures and techniques, and PCR devices and applications.

Padma Sundar has close to 15 years of experience in the genomics and molecular diagnostics industry with leadership roles in strategy, marketing, sales, and reimbursement at Oncocyte, Roche Sequencing, Guardant Health and Affymetrix. She is experienced in securing high value reimbursement values and launching multiple ground-breaking technologies in the oncology field. Padma began her career as a consultant with McKinsey and company. She has a bachelor’s in chemistry and an MBA and Masters in Public Health from UC Berkeley.

Paul has over twenty years experience in software development and scientific research. He has directed multiple teams developing industry-leading scientific software and has published in various areas including Molecular Modeling, Bioinformatics, Genetics and Molecular Evolution. Before joining ChromaCode, Paul led the BaseSpace development team at Illumina, where he oversaw commercialization and clinical transformation of the cloud genomics platform.

Chris is an experienced engineer and manager in the life sciences industry focused on data science, product engineering and process development. Most recently, he was an engineering manager at Illumina, leading the development of processes for consumables manufacturing across several major platforms, including the HiSeqX nanopatterned flowcell which enabled the $1000 genome.

Brett has over twenty years of experience in finance, corporate management, and human resources. He has worked in a broad range of industries and company sizes. His passion is helping companies with ground-breaking technology strategically expand their teams. At Luxtera, a pioneer in optics and electronic integration, he helped shape the company’s evolution from early research and development to initial revenue.

Crane is a business development professional with experience in genomic and cell therapy companies: large and small, public and private, Rx and Dx, including Illumina, TwinStrand, La Jolla Pharmaceutical Company, Monsanto and others. He has a passion for building collaborations that move well beyond zero-sum outcomes. His business development achievements have ranged from insourcing reagents, to closing novel and lucrative sales collaborations, to out-licensing non-core businesses.

Raees has more than 10 years of experience in commercial leading roles within diagnostics. He has extensive experience in sales (U.S. and International), business development and market access. Raees has worked at companies such as BioReference, Natera and PerkinElmer. Most notably he was early at Natera and achieved tremendous success in launching NIPT and Signatera. Raees also spent a couple of years as an Investment Banker at Royal Bank of Canada in NYC. Raees has a bachelors in Biochemistry and an MBA in Finance from University of Rochester.

Carol Gallagher is a Partner at NEA, joining in October, 2014. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. Prior to Calistoga she served in various leadership roles at both large pharma and small biotech. In addition to serving as a director at Chromacode, she serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, PIONYR Immunotherapeutics, XOC, and Qpex.https://www.nea.com/team/carol-gallagher

Alex is a life sciences executive with over 25 years experience leading strategic initiatives that have transformed small companies and enabled large companies to penetrate new markets. Most recently, he was the Senior Vice President of Strategic Initiatives at Illumina, Inc. where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems.

Mr. O’Boyle has over 20 years of executive management experience in the medical device industry. He was most recently Chairman of the Board of Directors at GenMark Diagnostics, a leading provider of sample-to-answer molecular diagnostic solutions acquired by Roche in March 2021. He has served in multiple leadership roles at Advanced BioHealing, Inc., NuVasive, Inc., and ChromaVision Medical Systems, Inc. Mr. O’Boyle is currently a member of the Board of Directors at Nevro and Sientra.

Mark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.

Aditya is the inventor of HDPCR, ChromaCode’s core technology. Previously, he was a researcher at Google[x], where he worked on novel medical imaging methods. He has expertise in thermal engineering, digital signal processing, nano-scale electronics, low-power circuit design for implantable sensors, DNA sequencing structures and techniques, and PCR devices and applications.

Pat is a Director at Northpond Ventures and a member of the firm’s leadership team. Pat supports investment activity for Northpond, including transaction valuation and due diligence, and leads deal negotiations. Formerly at PricewaterhouseCoopers, Pat has significant experience in accounting, financial operations and organizational best practices.https://northpondventures.com/team/#pat-smerkers-cpa

Jenny Yip is currently a Managing Partner at Adjuvant Capital, a dedicated global health investment fund backed by the Bill and Melinda Gates Foundation, with a focus on serving those living in low- and middle-income resource areas. Prior to joining Adjuvant, Jenny was a Partner at the Gates Foundation Strategic Investment Fund where she represented the Foundation's interests on numerous boards. Jenny also serves on the Investment Advisory Committee at the Reproductive Health Investors’ Alliance. Jenny joined the ChromaCode team in May of 2020. Jenny has worked in finance for more than 17 years beginning as an investment banker advising clients on mergers and acquisition at Goldman Sachs in Hong Kong, New York and San Francisco offices. Jenny graduated magna cum laude from Harvard University with an AB in History of Science.https://adjuvantcapital.com/team/

Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a leading venture capital and growth equity firm dedicated to medtech innovation. Justin was previously a partner and leader of the medical technology investing practice at NEA and worked at the Duke University Health System in strategy, operations, and finance. Justin currently or previously served on the board of directors of Apella, Cartiva (acquired), ChromaCode, Cleerly, Curate Biosciences, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular (acquired), Metavention, Personal Genome Diagnostics (acquired), PhaseBio Pharmaceuticals (IPO), Plexium, Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical (acquired), and VytronUS (acquired).

As ChromaCode’s first CEO from 2015-2021, Greg led the initiating and scale-up of the product research, development, commercial, finance and quality infrastructures. This included launching molecular assays and software products that generated over $60 million in revenue at >85% gross margins and, with his co-founders, raising $52 million in capital from three private funding rounds. Prior to ChromaCode, he spent 9 years at Luminex as VP/GM Biosciences and VP Global Sales and Marketing, when the company grew revenues from $30 million to over $200 million. Other experience includes strategic commercial roles at Nanogen, Chiron and BioRad. Greg has dual masters degrees in healthcare administration and business adminstration from the University of Minnesota and a bachelors in molecular, cellular and developmental biology from the University of Colorado.

Yaser is a Professor of Electrical Engineering and Computer Science at the California Institute of Technology, and Chairman of Machine Learning Consultants LLC. His main fields of expertise are machine learning and computational finance. He is the author of Amazon’s machine learning bestseller Learning from Data. His MOOC on machine learning has attracted more than two million views.

Michael has been an Engineering Director at Google since 2002 where his responsibilities have ranged from managing large engineering teams responsible for most of Google’s revenue, to overseeing critical internal software infrastructure projects. Michael currently leads a Google Research team that he founded, whose primary aim is to bring Google’s expertise in machine intelligence and machine perception to bear on fundamental scientific research.

Andrea is the Chair of the Division of Molecular Diagnostics in the Department of Pathology at the Virginia Commonwealth University Health System. She is also the director of the Molecular Diagnostics Laboratory at the VCU Health System.

Greg is the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center in Lebanon, NH and a Professor of Pathology at the Geisel School of Medicine at Dartmouth in Hanover, NH. He was the inaugural director of the molecular pathology laboratory at Hartford Hospital in Hartford, CT before going to Dartmouth.

Dr. Buchan is the Associate Director for Clinical Microbiology and Molecular Diagnostics. He oversees multiple aspects of the clinical microbiology laboratory including test interpretation, review of daily results, council of technologists, and serves a consultant to clinical colleagues involved in direct patient care. Academically, Dr. Buchan serves as Principal Investigator for numerous clinical trials involving new diagnostic assays for the identification of bacterial, viral and fungal pathogens and is a member of the editorial board for the Journal of Clinical Microbiology and the American Journal for Clinical Pathology.